BIOCRYST PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
Clinical Trials
87
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (67 trials with phase data)• Click on a phase to view related trials
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT06539507
- Locations
- 🇦🇺
Investigative site, Brisbane, Queensland, Australia
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06100900
- Locations
- 🇿🇦
BioCryst Investigative Site, Pretoria, South Africa
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT05741346
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Berotralstat Treatment in Children With Hereditary Angioedema
- Conditions
- Hereditary AngioedemaPediatric
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT05453968
- Locations
- 🇬🇧
Investigative Site #1, Bristol, United Kingdom
🇫🇷Investigative Site #3, Grenoble, France
🇪🇸Investigative Site #2, Málaga, Spain
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
- Conditions
- Complement 3 GlomerulopathyImmunoglobulin A NephropathyMembranous Nephropathy
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05162066
- Locations
- 🇬🇧
Investigative Site, Oxford, United Kingdom
🇪🇸Investigative Site #1, Madrid, Spain
🇪🇸Investigative Site #2, Madrid, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.
BioCryst Names Charlie Gayer as New CEO Following Jon Stonehouse's Retirement Announcement
BioCryst Pharmaceuticals announced that CEO Jon Stonehouse will retire on December 31, 2025, with current Chief Commercial Officer Charlie Gayer set to succeed him as president in August and CEO in January 2026.
BioCryst Pharmaceuticals Appoints Babar Ghias as CFO and Head of Corporate Development
BioCryst Pharmaceuticals has appointed Babar Ghias as chief financial officer and head of corporate development, bringing extensive deal-making experience from rare disease companies.
BioCryst Pharmaceuticals Divests European ORLADEYO Rights for $264 Million to Achieve Debt-Free Status
BioCryst Pharmaceuticals sold its European commercial rights to ORLADEYO, a C1 inhibitor therapy for hereditary angioedema, to Neopharmed Gentili for up to $264 million on June 27, 2025.
IgA Nephropathy Pipeline Shows Robust Growth with 30+ Therapies in Development
DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ therapies for IgA nephropathy treatment, representing a robust therapeutic landscape.
BioCryst's Orladeyo Demonstrates Safety and Efficacy in Pediatric Hereditary Angioedema Trial
Interim analysis of APeX-P trial shows Orladeyo (berotralstat) oral granule formulation is safe and well-tolerated in children aged 2-12 years with hereditary angioedema.
BioCryst's Orladeyo® (berotralstat) Receives Recommendation in Ireland for HAE Prophylaxis
The Health Services Executive (HSE) in Ireland has recommended Orladeyo® (berotralstat) for routine prevention of recurrent hereditary angioedema (HAE) attacks in eligible patients 12 years and older.
Clearside Biomedical's CLS-AX Phase IIb Trial Readout Anticipated in Q3 2024
• Clearside Biomedical anticipates primary data readout from its Phase IIb ODYSSEY trial of CLS-AX for wet AMD in Q3 2024, assessing its potential as a maintenance therapy. • The company's SCS Microinjector continues to demonstrate benefits in suprachoroidal drug delivery, with multiple partnerships and clinical trials underway for various indications. • A new collaboration with BioCryst Pharmaceuticals will utilize Clearside's SCS Microinjector to deliver their compound aboard Elestat for treating diabetic macular edema. • Clearside Biomedical's cash balance, including proceeds from a recent offering, is expected to fund operations into Q3 2025, supporting the CLS-AX Phase III program.